UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8
UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.
Stocks · News reference
China National Intellectual Property Administration Awards Maravai LifeSciences's TriLink BioTechnologies Patent Number ZL202511246658.5., Named "Compositions and Methods for Synthesizing 5'-Capped RNAs."
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday
Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX, SCSC, BTBT, MRVI, HIVE, AHG, TEM, MARA, LB also gain.
Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.